Publications

Prolonged analgesia from Bupisome and Bupigel formulations: From design and fabrication to improved stability

Rivka Cohen, Hiba Kanaan, Gilbert J. Grant, Yechezkel Barenholz
Journal of Controlled Release

Based on data from early animal studies, Probudur has indicated post-operative control for up to 96 hours, which is 24 hours longer than the leading product on the market. If we are able to demonstrate a successful Phase III clinical trial, we believe Probudur may represent the first long acting local anesthetic with an opioid sparing label.

Liposomal Bupivacaine (Bupigel) Demonstrates Minimal Local Nerve Toxicity in a Rabbit Functional Model

Yaelle Bavli, Malcolm Rabie, Yakov Fellig, Yoram Nevo, and Yechezkel Barenholz
Pharmaceutics

Engineering precision nanoparticles for drug delivery

Michael J. Mitchell, Margaret M. Billingsley, Rebecca M. Haley, Marissa E. Wechsler, Nicholas A. Peppas & Robert Langer
Nature Reviews Drug Discovery

“We focus on advances in nanoparticle design that overcome heterogeneous barriers to delivery, arguing that intelligent nanoparticle design can improve efficacy in general delivery applications while enabling tailored designs for precision applications, thereby ultimately improving patient outcome overall.”

Delta Opioid Receptor-Mediated Antidepressant-Like Effects of Diprenorphine in Mice

Keith M. Olson, Todd M. Hillhouse, Gwendolyn E. Burgess, Joshua L. West, James E. Hallahan, Isaac J. Dripps, Allison G. Ladetto, Kenner C. Rice, Emily M. Jutkiewicz and John R. Traynor
Journal of Pharmacology and Experimental Therapeutics

“Here we show that the opioid diprenorphine, a compound with mu-opioid receptor antagonist activity and delta- and kappa-opioid receptor partial agonist activities, has rapid onset antidepressant-like activity in animal models.“

Nanoparticulate peptide delivery exclusively to the brain produces tolerance free analgesia

Lisa Godfrey, Antonio Iannitelli, Natalie L. Garrettc, Julian Moger, Ian Imbert, Tamara King, Frank Porreca, Ramesh Soundararajan, Aikaterini Lalats, Andreas G. Schätzlein, Ijeoma F. Uchegbu
Journal of Controlled Release

There is pharmacological evidence of activity of MET enabled enkephalin in morphine-tolerant animals.

We believe the preliminary data from these early animal studies of NES100 support our belief that Envelta™ may have comparable preclinical activity to morphine in all animal pain models tested without the drug seeking, respiratory depression, and tolerance associated with opioids.

Currently, enkephalins are limited in their therapeutic potential by their pharmacokinetic profiles due to their inability to cross the blood-brain barrier to reach opioid receptors located in the central nervous system.

Targeting Alternative Opioid Receptor Reduces Drug Side Effects

Sara E. Teller
Legal Reader

Endosomal signaling of delta opioid receptors is an endogenous mechanism and therapeutic target for relief from inflammatory pain

Nestor N. Jimenez-Vargas, Jing Gong, Matthew J. Wisdom, Dane D. Jensen, Rocco Latorre, Alan Hegron, Shavonne Teng, Jesse J. DiCello, Pradeep Rajasekhar, Nicholas A. Veldhuis, Simona E. Carbone, Yang Yu, Cintya Lopez-Lopez, Josue Jaramillo-Polanco, Meritxell Canals, David E. Reed, Alan E. Lomax, Brian L. Schmidt, View ORCID ProfileKam W. Leong, Stephen J. Vanner, Michelle L. Halls, Nigel W. Bunnett, and Daniel P. Poole
National Academy of Sciences

Leucine-Enkephalin as a Novel Analgesic: Efficacy and Safety in Pre-Clinical Models

Presented by Dr. Jeff Gudin at the 3rd Annual NIH HEAL Investigator Initiated Meeting

Facts About Cancer Pain

From American Cancer Society

Engineering precision nanoparticles for drug delivery

Michael J. Mitchell, Margaret M. Billingsley, Rebecca M. Haley, Marissa E. Wechsler, Nicholas A. Peppas & Robert Langer
Nature Reviews Drug Discovery

“We focus on advances in nanoparticle design that overcome heterogeneous barriers to delivery, arguing that intelligent nanoparticle design can improve efficacy in general delivery applications while enabling tailored designs for precision applications, thereby ultimately improving patient outcome overall.”

FDA U.S. Food & Drug Administration – Action Plan for Rare Neurodegenerative Diseases including Amyotrophic Lateral Sclerosis

A five-year action plan developed to meet requirements under Section 4 of the Accelerating Access to Critical Therapies for ALS Act.

Forms of Rare Pediatric Epilepsy

The Evolving Nature of Lennox-Gastaut Syndrome and Dravet Syndrome

Greenwich Biosciences, Inc

Patient-Centered Outcomes Research in Dravet Syndrome

Dravet Syndrome Foundation